Borden EC - Search Results

1

Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma.

Raychaudhuri B, Rayman P, Ireland J, Ko J, Rini B, Borden EC, Garcia J, Vogelbaum MA, Finke J. Raychaudhuri B, et al. Among authors: borden ec. Neuro Oncol. 2011 Jun;13(6):591-9. doi: 10.1093/neuonc/nor042. Neuro Oncol. 2011. PMID: 21636707 Free PMC article.

2

A phase I study of sunitinib plus bevacizumab in advanced solid tumors.

Rini BI, Garcia JA, Cooney MM, Elson P, Tyler A, Beatty K, Bokar J, Mekhail T, Bukowski RM, Budd GT, Triozzi P, Borden E, Ivy P, Chen HX, Dolwati A, Dreicer R. Rini BI, et al. Clin Cancer Res. 2009 Oct 1;15(19):6277-83. doi: 10.1158/1078-0432.CCR-09-0717. Epub 2009 Sep 22. Clin Cancer Res. 2009. PMID: 19773375 Free PMC article. Clinical Trial.

3

Phase I trial of consensus interferon in patients with metastatic renal cell carcinoma: toxicity and immunological effects.

Hutson TE, Molto L, Mekhail T, Elson P, Finke J, Tannenbaum C, Borden E, Dreicer R, Olencki T, Bukowski RM. Hutson TE, et al. Clin Cancer Res. 2003 Apr;9(4):1354-60. Clin Cancer Res. 2003. PMID: 12684404 Clinical Trial.

4

Dual VEGF/VEGFR inhibition in advanced solid malignancies: clinical effects and pharmacodynamic biomarkers.

Mittal K, Koon H, Elson P, Triozzi P, Dowlati A, Chen H, Borden EC, Rini BI. Mittal K, et al. Among authors: borden ec. Cancer Biol Ther. 2014 Aug;15(8):975-81. doi: 10.4161/cbt.29187. Epub 2014 May 19. Cancer Biol Ther. 2014. PMID: 24842548 Free PMC article. Clinical Trial.

5

Phase 2 trial of interferon-beta as second-line treatment of ovarian cancer, fallopian tube cancer, or primary carcinoma of the peritoneum.

Markman M, Belinson J, Webster K, Zanotti K, Morrison B, Jacobs B, Borden E, Lindner D. Markman M, et al. Oncology. 2004;66(5):343-6. doi: 10.1159/000079480. Oncology. 2004. PMID: 15331919 Clinical Trial.

6

Intraperitoneal administration of interferon-gamma to carcinoma patients enhances expression of tumor-associated glycoprotein-72 and carcinoembryonic antigen on malignant ascites cells.

Greiner JW, Guadagni F, Goldstein D, Smalley RV, Borden EC, Simpson JF, Molinolo A, Schlom J. Greiner JW, et al. Among authors: borden ec. J Clin Oncol. 1992 May;10(5):735-46. doi: 10.1200/JCO.1992.10.5.735. J Clin Oncol. 1992. PMID: 1569446

7

Interferon-gamma is induced in human peripheral blood immune cells in vitro by sodium stibogluconate/interleukin-2 and mediates its antitumor activity in vivo.

Fan K, Borden E, Yi T. Fan K, et al. J Interferon Cytokine Res. 2009 Aug;29(8):451-60. doi: 10.1089/jir.2008.0061. J Interferon Cytokine Res. 2009. PMID: 19514839 Free PMC article.

8

Melanoma 2007: current state and preview of the future.

Borden EC. Borden EC. Semin Oncol. 2007 Dec;34(6):449-51. doi: 10.1053/j.seminoncol.2007.09.001. Semin Oncol. 2007. PMID: 18083367 No abstract available.

9

Resistance to interferons in melanoma cells does not correlate with the expression or activation of signal transducer and activator of transcription 1 (Stat1).

Chawla-Sarkar M, Leaman DW, Jacobs BS, Tuthill RJ, Chatterjee-Kishore M, Stark GR, Borden EC. Chawla-Sarkar M, et al. Among authors: borden ec. J Interferon Cytokine Res. 2002 May;22(5):603-13. doi: 10.1089/10799900252982089. J Interferon Cytokine Res. 2002. PMID: 12060499

10

Sodium stibogluconate interacts with IL-2 in anti-Renca tumor action via a T cell-dependent mechanism in connection with induction of tumor-infiltrating macrophages.

Fan K, Zhou M, Pathak MK, Lindner DJ, Altuntas CZ, Tuohy VK, Borden EC, Yi T. Fan K, et al. Among authors: borden ec. J Immunol. 2005 Nov 15;175(10):7003-8. doi: 10.4049/jimmunol.175.10.7003. J Immunol. 2005. PMID: 16272361

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

308 results

Search Page